Musical chairs at GSK leaves Stout out

You can take your $4 million and keep it. David Stout (photo), GlaxoSmithKline's president of pharmaceutical operations, evidently wants no part of the reported $4 million incentive package he was offered after being passed up for the top job. The company reported this morning that he's on the way out, while another frustrated candidate, Chris Viehbacher (photo), president of U.S. pharmaceuticals, joins the board. No word yet on where Stout may land. Andrew Witty (photo), new chief, also took his place on the board. And Eddie Gray, currently senior vice president and general manager pharmaceuticals UK, will succeed Witty as president, pharmaceuticals Europe.

- check out the release on the executive moves

Related Articles:
GSK runners-up get $4M, board seat. Report
GSK CEO also-rans may get on board. Report
At GSK, a public race for the top spot. Report
Just who is Glaxo's Andrew Witty? Report
GSK taps Witty as next CEO. Report

Suggested Articles

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…

Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.